Baidu
map

果断收藏!全面总结婴幼儿安全用药指南!

2015-12-29 佚名 合理用药百科微信号

一、抗生素、磺胺类、喹诺酮类安全用药:青霉素、氯唑西林钠、哌拉西林钠(皮试阳性者禁用)、奈替米星、红霉素;慎用药物:头孢曲松、头孢菌素(皮试阳性者禁用)、β-内酰胺酶抑制剂、氨基糖苷类 链霉素、庆大霉素、卡那霉素、丁胺卡那霉素、罗红霉素、琥乙红霉素、阿奇霉素、氯霉素类、磺胺类、喹诺酮类;禁用药物:四环素类、磺胺类、抗真菌类药;依托红霉素。1、 青霉素类常用的有青霉素、氯唑西林钠、哌拉西林钠等。

一、抗生素、磺胺类、喹诺酮类

安全用药:青霉素、氯唑西林钠、哌拉西林钠(皮试阳性者禁用)、奈替米星、红霉素;

慎用药物:头孢曲松、头孢菌素(皮试阳性者禁用)、β-内酰胺酶抑制剂、氨基糖苷类 链霉素、庆大霉素、卡那霉素、丁胺卡那霉素、罗红霉素、琥乙红霉素、阿奇霉素、氯霉素类、磺胺类、喹诺酮类;

禁用药物:四环素类、磺胺类、抗真菌类药;依托红霉素。

1、 青霉素类

常用的有青霉素、氯唑西林钠、哌拉西林钠等。青霉素类对人体细胞毒性很低,有效抗菌浓度的青霉素对人体几乎无影响。临床应用时青霉素较多出现过敏反应,小儿3日内未使用青霉素类药物应进行皮试,阳性者禁用。

2、 头孢菌素类

使用前应作皮试,阳性者禁用。头孢曲松偶可致婴幼儿胆结石,但停药后可消失。头孢菌素与高效利尿药或氨基糖苷类合用肾损害显著增强,与乙醇(即使很小量)联合应用时,可引起体内乙醛蓄积,而显“醉酒样”反应。

3、β-内酰胺酶抑制剂

过敏体质者应慎用。

4、 氨基糖苷类

链霉素、庆大霉素、卡那霉素、丁胺卡那霉素均对耳蜗神经有毒性,幼儿慎用,如使用应减小剂量,且疗程不超过7天。奈替米星耳毒性较小,新生儿、婴幼儿均可使用,但应掌握好剂量

5、 四环素类

该类药物除有肝肾损害以外,还可沉积于牙齿和骨骼中,造成牙齿黄染,影响婴幼儿骨骼正常发育,因此8岁以下儿童应禁用。

6、大环内酯类

红霉素毒性低,可用。罗红霉素、琥乙红霉素、阿奇霉素使用时应注意剂量。常见的不良反应有肝毒性、听觉障碍、过敏(主要表现为药物热、药疹、荨麻疹)等,停药或减量可恢复,但患儿合并肝炎时,应禁用依托红霉素。

7、氯霉素类

主要不良反应有粒细胞及血小板减少,再生障碍性贫血等,慎用。

8、磺胺类

对体内葡萄糖-6磷酸脱氢酶缺乏的乳儿可致正铁血红蛋白血症和溶血性贫血,应禁用。幼儿使用应注意大量饮水防止引起结晶尿。还可致损害肝、肾和周围神经炎等,应慎用。

9、喹诺酮类

该类药物可影响软骨发育,婴幼儿应慎用。但也有不良反应低的报道。

10、其他类

抗真菌类药对肝、肾功能损害大,慎用。乙胺丁醇婴幼儿应禁用。 

二、驱肠虫药

安全用药:甲苯咪唑(4岁以下用量减半)、哌嗪(驱蛔灵)

慎用药物:肠虫清(2岁以下禁用,2~12岁用量减半)

1、 阿苯达唑(肠虫清) 广谱驱虫药,对肝肾功能有一定损害,2岁以下儿童禁用,2~12岁用量减半。

2、 甲苯咪唑 4岁以下用量减半。

3、 哌嗪(驱蛔灵) 本品毒性低,用量用法应在医生/药师指导下使用。

三、作用于中枢神经系统的药

安全用药:扑热息痛类、抗癫痫

慎用药物:氨基比林、阿司匹林、哌替啶(杜冷丁)

禁用药物:非那西丁类、苯巴比妥(12岁以下儿童禁用)、吗啡、芬太尼贴片

1、解热镇痛类

(1)非那西丁类:主要是指含有非那西丁的复方制剂,可引起人体高铁血红蛋白血症和肾损害,对婴幼儿尤其敏感,禁用。

(2)氨基比林:首要损害是粒细胞减少,慎用。

(3)阿司匹林:患有呼吸系统疾病的儿童慎用。对小儿易引起瑞氏综合征,英国规定12岁以内儿童禁用。

(4)扑热息痛类:相对安全,可用。 

2、镇静催眠药

苯巴比妥等此类药物,对中枢神经系统有广泛的抵制作用,12岁以下儿童禁用。

3、镇痛药

哌替啶(度冷丁):婴幼儿慎用。

吗啡、芬太尼贴片:婴幼儿禁用。

1岁以内一般不应静脉注射或行人工冬眠。

4、抗癫痫药

一般长期服用癫痫药物是安全的,药物毒性反应轻微而且是可逆的,但应在治疗中注意中毒表现,定期做血、尿常规等多项检查。

四、呼吸系统用药

安全用药:必嗽平;平喘药 ;

慎用药物:氯化铵、复方甘草片;

禁用药物:喷托维林(咳必清); 

1、祛痰药

氯化铵一定要计算好用量,大剂量可致恶心、呕吐,停药后反应消失。必嗽平一般无不良反应,可用。喷托维林(咳必清)有报道可造成呼吸抑制,故禁用。复方甘草片含有阿片粉成分,应注意剂量。

2、平喘药

作为非处方药,不推荐儿童应用,儿童哮喘应及时到医院诊治。此类药物的给药途径多种多样的,可以口服、静脉、喷雾吸入给药。喷雾和吸入给药具有速效性、安全性和方便性。

3、来源于中草药的祛痰、镇咳、平喘药,均须严格计算好剂量。 

五、消化系统用药

安全用药:乳酶生、干酵母、蒙脱石散剂、妈咪爱;

慎用药物:胃肠解痉药、多潘立酮、酚酞片(1~3岁);

禁用药物:西米替丁、酚酞片(1岁以下)、易蒙停(1岁以下)、药用炭; 

1、抗酸药

婴幼儿胃病较少见。西米替丁8岁以下儿童禁用。

2、胃肠解痉药

婴幼儿的急性腹痛,以肠道寄生虫、胆道蛔虫、阑尾蛔虫等多见,不应轻易使用此类药物,避免延误病情,应在全面尤其是腹部检查后酌情应用。

3、助消化药

乳酶生可用,但不与抗菌药合用。

干酵母不良反应少,可用,但大剂量可引起腹泻。

多潘立酮:婴幼儿血脑屏障功能未完全发育,可能引起神经方面的副作用,1岁以下慎用。

4、泻药

一般来说,儿童不应用缓泻药,有些父母错误的认为必须每天排便而给孩子使用泻药,这样可能会造成缓泻药依赖性便秘。如必须使用,应严格掌握剂量,并配合饮食与运动治疗。

酚酞片:婴儿(1岁以下)禁用,幼儿(1~3岁)慎用。

5、止泻药

洛哌丁胺(易蒙停)1岁以下婴儿应禁用。严重脱水的小儿不宜使用。

蒙脱石散剂:疗效好,可用。

妈咪爱:疗效确切,可用。

药用炭可影响儿童的影响吸收,婴幼儿如长期腹泻或腹胀禁用。

六、抗贫血药

安全用药:叶酸、硫酸亚铁(饭后服用)

硫酸亚铁对胃粘膜有刺激性,可致恶心、呕吐、上腹痛、腹泻等,可饭后服用。叶酸不良反应较少,可用。 

七、抗变态反应药物

慎用药物:扑尔敏、盐酸苯海拉明、富马酸酮替芬

马来酸氯苯那敏(扑尔敏)、盐酸苯海拉明、富马酸酮替芬等此类药物对中枢神经系统有抵制作用,婴幼儿应慎用。

八、激素类

慎用药物:激素类

激素及其有关药物大剂量或长期应用本类药物可引起肥胖、多毛、骨质疏松、脱钙、病理性骨折、伤口愈合不良等反应,因此婴幼儿应慎用。

九、维生素类

安全用药:维生素A、维生素D、维生素C

1、维生素A

长期大剂量可引起维生素A过多症,甚至发生急性或慢性中毒,婴幼儿发生率最高,表现为骨痛、骨折、食欲不振、脱发、易激动等,停药1~2周可消失。 

2、维生素D

大量久服,可引起高血钙、食欲不振、呕吐、腹泻,甚至软组织异位骨化等,婴幼儿为预防维生素D缺乏补充时,应掌握好剂量。

3、维生素C

过量服用会产生胃肠道反应和肾、膀胱结石易于形成。

十、外用药

慎用药物:鼻眼净、皮质激素软膏、阿托品滴眼剂

由于小儿皮肤、粘膜面积相对较大,吸收功能强,注意剂量。鼻眼净治疗婴儿鼻炎,能引起昏迷、呼吸暂停、体温过低,慎用。皮质激素软膏大面积外用,可引起全身水肿,慎用。

阿托品滴眼剂:婴幼儿对此药中毒,滴时应压迫泪囊,以防止进入鼻腔吸收而中毒,慎用。 

十一、其他类

慎用药物:锌制剂、人参蜂王浆、至宝锭、一捻金;

锌制剂过量引起恶心、呕吐、发热、贫血等毒性反应。人参蜂王浆含有激素样物质,服用过量,可出现儿童发育早熟现象。至宝锭、一捻金等儿科类中成药主要成分中含有朱砂,服用过多易引起服痛、恶心、呕吐等汞中毒症状。

婴幼儿用药小贴士---

1、避免应用禁用药物;

2、需用慎用药物时,应在临床医师/药师指导下用药,并应密切观察病情变化及治疗中的药物反应;

3、注意给药途径及方法的选择,由于孩子吞咽能力差,又不懂事,用药时很难与大人配合,所以要选择适宜的剂型。一般若无消化道和其它影响孩子口服的因素,能以口服或局部用药较好,如口服不便可考虑肛门给药或其他;

4、根据婴幼儿的年龄、体重、体表面积等正确计算合理的给药剂量。剂量不足不仅会延误病情,还易产生抗药性, 剂量过大又会引起不良反应。

5、无病时别乱服药,俗话说“是药三分毒”。大多数药物在体内代谢过程中要经过肝脏的解毒和肾脏的排泄。3岁前的孩子各脏器的功能尚不完善,如用药不当,对宝宝健康不利。 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-02-16 mengli1984

    值得学习!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-01-24 1de3b290m83(暂无匿称)

    小心用药

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-01-13 Lynee劲飞扬

    需要积分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-30 张新苹

    不错!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-30 田田1746

    总结的不错,不知道出处

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 dhzzm

    学习了,很值

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1692981, encodeId=11b9169298129, content=<a href='/topic/show?id=a45e45e347b' target=_blank style='color:#2F92EE;'>#安全用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45734, encryptionId=a45e45e347b, topicName=安全用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82329318269, createdName=般若傻瓜, createdTime=Thu Aug 04 00:35:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64470, encodeId=afc4644e0f0, content=值得学习!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 20:01:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59050, encodeId=389e5905029, content=小心用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sun Jan 24 18:34:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56805, encodeId=c54f568056b, content=需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Wed Jan 13 11:47:00 CST 2016, time=2016-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50568, encodeId=cdf25056880, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151105/IMG563B1F6599ADF7132.jpg, createdBy=605a1636591, createdName=张新苹, createdTime=Wed Dec 30 16:29:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50369, encodeId=c8f550369f8, content=总结的不错,不知道出处, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=42b01658905, createdName=田田1746, createdTime=Wed Dec 30 06:31:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50347, encodeId=fa1b5034ec1, content=学习了,很值, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:50:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50342, encodeId=ba595034277, content=棒,大拇指上, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Tue Dec 29 21:21:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 三三五五

    棒,大拇指上

    0

相关资讯

JAMA:水解配方婴儿奶粉并不减少婴幼儿的I型糖尿病风险(TRIGR 研究)

一般来说,I型糖尿病往往从婴幼儿阶段就开始,但详细的病因尚不清楚。有些研究认为早期暴露于复杂的膳食蛋白质可能会增加β-细胞自身免疫作用,从而增加患儿的I型糖尿病的风险。而深度水解配方的奶粉不含有完整的蛋白质成分,对婴儿的β细胞自身免疫是否安全呢,由全球15个国家78个中心发起的一项全球多中心临床试验,验证水解配方婴儿奶粉的安全性。研究目的:检验断奶到水解配方降低了幼儿糖尿病相关的自身抗体的累积发生

NICE指南:儿童胃食管反流病

胃食管反流是一种正常的生理现象,但是当其可致严重症状而需治疗或引起并发症时则称为胃食管反流病(GORD)。在婴幼儿和儿童中,由于存在各种潜在症状且缺乏简单可靠、能广泛使用的诊断性检测方法,故难以鉴别生理性胃食管反流和病理性胃食管反流病,这会导致极大的临床实践差异。 该病可影响儿童,包括早产和足月新生儿、健康婴幼儿和儿童及确定有明确危险因素的患儿,如膈疝修补术后、其他先天性畸形、严重的

BMJ Open:小心庸医!上海不建议使用针灸治疗婴幼儿

当代上海中医药从业人员不推荐使用针灸治疗婴幼儿。针灸对婴幼儿疾病有广泛适应症似乎是西医经验,没有多少中医药学现代实践基础。

肺炎链球菌疫苗成人也应接种

  11月6日,由中华预防医学会制定的《肺炎链球菌性疾病相关疫苗应用技术指南(2012版)》在京发布。与2009版指南相比,新版指南不仅推荐儿童全程接种疫苗,还建议免疫功能受损的成人等接种疫苗。   据介绍,肺炎链球菌广泛存在于自然界,可通过咳嗽或者打喷嚏引起人间传播并长时间潜伏在人体内,婴幼儿鼻咽部携带率明显高于成人。而肺炎链球菌一旦侵入人体的不同部位,可引起鼻窦炎、中耳炎、肺炎、脑膜炎、菌血

贫困地区儿童营养改善试点项目启动

  由卫生部和全国妇联主办的贫困地区儿童营养改善试点项目10月15日在山西省太原市启动。今后,山西陕西吕梁山区、湖北湖南重庆贵州武陵山区、云南滇西边境山区等8个国家集中连片特困地区100个县6月龄~2岁的婴幼儿,将获得免费的辅食营养补充品(即营养包),以预防婴幼儿营养不良和贫血。中央财政将提供专项补助经费。这是医改针对儿童的又一个重大公共卫生服务项目,也是第一个专为集中连片特殊困难地区量身定制的卫

Baidu
map
Baidu
map
Baidu
map